A study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).

dc.contributor.authorAbali, Huseyin
dc.contributor.authorYalcin, Suayib
dc.contributor.authorOnal, Huseyin Cem
dc.contributor.authorDane, Faysal
dc.contributor.authorOksuzoglu, Berna
dc.contributor.authorOzdemir, Nuriye
dc.contributor.authorMertsoylu, Huseyin
dc.contributor.authorArtac, Mehmet
dc.contributor.authorCamci, Celalettin
dc.contributor.authorKarabulut, Bulent
dc.contributor.authorBasal, Fatma Bugdayci
dc.contributor.authorBudakoglu, Burcin
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorGoktas, Burce
dc.contributor.authorOzdener, Fatih
dc.contributor.authorCalisgan, Arzu
dc.date.accessioned2019-10-27T23:11:24Z
dc.date.available2019-10-27T23:11:24Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.descriptionGastrointestinal Cancers Symposium -- JAN 21-23, 2016 -- San Francisco, CAen_US
dc.identifier.doi10.1200/jco.2016.34.4_suppl.tps182
dc.identifier.issn0732-183X
dc.identifier.issn1527-7755
dc.identifier.issue4en_US
dc.identifier.urihttps://doi.org/10.1200/jco.2016.34.4_suppl.tps182
dc.identifier.urihttps://hdl.handle.net/11454/53070
dc.identifier.volume34en_US
dc.identifier.wosWOS:000378109600176en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherAmer Soc Clinical Oncologyen_US
dc.relation.ispartofJournal of Clinical Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleA study of the combination of oxaliplatin, capecitabine, and herceptin (trastuzumab) and chemoradiotherapy in the adjuvant setting in operated patients with HER2+gastric or gastro-esophageal junction cancer (TOXAG study).en_US
dc.typeConference Objecten_US

Dosyalar